Information Provided By: 
Fly News Breaks for September 11, 2015
OPK
Sep 11, 2015 | 06:29 EDT
Jefferies analyst Brandon Couillard downgraded OPKO Health to Hold after assuming coverage of the stock. Additional studies of the company's blood-based 4Kscore test are needed for broad payor coverage, Couillard tells investors in a research note. Further, the acquisition of Bio-Reference Laboratories, while adding a stable $1B revenue base, reduces OPKO's earnings quality, the analyst believes. He raised his price target for the stock to $11 from $10.
News For OPK From the Last 2 Days
There are no results for your query OPK
